Prospective Study to Revise the Ottawa Heart Failure Risk Scale (OHFRS)

Similar documents
The Canadian Syncope Risk Score to Identify Patients at Risk for SAE after ED Disposition

Clinical validation of a risk scale for serious outcomes among patients with chronic obstructive pulmonary disease managed in the emergency department

Adverse Outcomes in ED Pre Syncope Patients: A Prospective Cohort Study

9/14/2017 HEART FAILURE IN OBS NO RELEVANT DISCLOSURES IRRELEVANT DISCLOSURES OBJECTIVES WHY HEART FAILURE

Biomarkers in the Assessment of Congestive Heart Failure

University of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

Mohammad Zubaid, MB, ChB, FRCPC, FACC

KEEPING YOUR PATIENT OUT OF THE HOSPITAL BY PREVENTING A SECOND STROKE

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

Emergency Medicine Research: Creating Evidence to Improve Safety and Effectiveness of ED Patient Care

Cardiology Department Coimbra Hospital and Medical School Portugal

Comfort with Geriatric Emergency Medicine Competencies: A Survey of Canadian Emergency Medicine Residents

Canadian Stroke Best Practices Initial ED Evaluation of Acute Stroke and Transient Ischemic Attack (TIA) Order Set (Order Set 1)

Hemodynamic, management, and outcomes of patients admitted to emergency department with heart failure

Patient characteristics Intervention Comparison Length of followup

NITROGLYCERIN A NEW LOOK FOR AN OLD FRIEND. Casey Patrick MD Jordan Anderson LP, CCP-C Texas EMS November 19, 2018

Selective Cardiac Myosin Activators in Heart Failure

Data Elements and Definitions with Case Studies. Interpreting Your Outcomes Reports. Kim Hustler, Clinical Quality Consultant, NCDR

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

ARTICLE IN PRESS. doi: /j.jemermed TRAUMA PATIENTS CAN SAFELY BE EXTUBATED IN THE EMERGENCY DEPARTMENT

Heart Failure 101 The Basic Principles of Diagnosis & Management

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

STEMI, Non-STEMI, Chest Pain?

Early release, published at on July 4, Subject to revision.

OBSERVATION UNIT ASTHMA PATHWAY OUTLINE Westmoreland Hospital PAGE 1 OF 5

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Updates in Congestive Heart Failure

Oxygen and ABG. Dr Will Dooley

Level 1: Acute CHF with Hypotension (SBP < 90 torr)

Use of Sacubitril/Valsartan in Heart Failure

What s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM

Debate: Do Rapid Response Systems Dumb Down Floor Staff? YES (or at least a qualified yes) Randy Wax, MD, MEd, FRCPC, FCCM

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

IDENTIFYING SEPSIS IN THE PREHOSPITAL SETTING

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.

Occurrence of Bleeding and Thrombosis during Antiplatelet therapy In Non-cardiac surgery. A prospective observational study.

A walk through a STEMI

Supplementary Appendix

Benoy N Shah 1,2,3, Gothandaraman Balaji 1, Abdalla Alhajiri 1, Ihab Ramzy 1, Shahram Ahmadvazir 1 & Roxy Senior 1,2,3

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

NHS QIS National Measurement of Audit Acute Coronary Syndrome

Use of Biomarkers for Detection of Acute Myocardial Infarction

Clinical Decision Rules to Rule Out Subarachnoid Hemorrhage for Acute Headache FREE

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Synopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable

Variables in Riksstroke - TIA

4. Which survey program does your facility use to get your program designated by the state?

Prospective Validation of a Clinical Decision Rule to Identify ED Chest Pain Patients Who Can Safely be Removed from Cardiac Monitoring

Unnecessary hospitalisation and investigation of low risk patients presenting to hospital with chest pain

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance in Non-Ischemic Heart Failure (IMAGE-HF project 1B)

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group

Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial

The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP

Daily practice of ACS management in the Gulf: Data from Gulf COAST

TACO CASE STUDIES RTC JUNE Kerry Dowling Blood Transfusion Laboratory Manager Jonathan Ricks Blood Transfusion Nurse Practitioner

CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin

Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

RESULTS: We included 796 patients (mean age 63.8 yr, 55.8% male, 8.9% admitted to hospital). Fifteen patients (1.9%) had an arrhythmia, and the rule

VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE

and Treatment in Emergency Care) Trial: Intravenous Glucose, Insulin & Potassium (GIK) in Emergency Medical Services

A CLINICAL DECISION TOOL FOR DIAGNOSING ACUTE HEART FAILURE IN THE UNDIFFERENTIATED DYSPNEIC ED PATIENT

Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction

KICU Spontaneous Awakening Trial (SAT) Questionnaire

ST-elevation myocardial infarctions (STEMIs)

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy

Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham

The National Heart Failure Audit 2010/2011

Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)

APPLYING THE CTAS to Appropriately Prioritize the Elderly

Canadian CT Head Rule Study for Patients With Minor Head Injury: Methodology for Phase II (Validation and Economic Analysis)

In-Patient Sleep Testing/Management Boaz Markewitz, MD

Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa

NES Asthma Hospital Medication Care Plan 7

County of Santa Clara Emergency Medical Services System

Disclosure. Co-investigators 1/23/2015

DISCUSSION QUESTION - 1

convey the clinical quality measure's title, number, owner/developer and contact

The Prehospital Validation of the Canadian C-Spine Rule by Paramedics

AF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management

Early-goal-directed therapy and protocolised treatment in septic shock

Section A: Clarification on effectiveness data. Licensed population

Early discharge in selected patients after an acute coronary syndrome can it be safe?

The Atrial Fibrillation Clinic in Llanelli. Dr Lena Marie Izzat Consultant Cardiovascular Physician

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

Congestive Heart Failure: Outpatient Management

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Learning Lessons from Complaints to the Ombudsman Charles Turton. Society for Acute Medicine May 2013

9/15/2017. Joyce Turner RN Director of Clinical Program Development

The San Francisco Syncope Rule to Predict Patients with Serious Outcomes

(For items 1-12, each question specifies mark one or mark all that apply.)

Diabetes and the Heart

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

Suspected Renal Colic in the Emergency Department

Transcription:

Prospective Study to Revise the Ottawa Heart Failure Risk Scale (OHFRS) CAEP Edmonton 2015

Ian Stiell MD Shawn Aaron MD Robert Brison MD Alan Forster MD Jeffrey Perry MD George Wells PhD Catherine Clement RN Bjug Borgundvaag MD Lisa Calder MD Andrew McRae MD Brian Rowe MD Department of Emergency Medicine Ottawa Hospital Research Institute University of Ottawa, Ottawa, ON Queens University, Kingston, ON University of Alberta, Edmonton, AB University of Toronto, Toronto, ON University of Calgary, Calgary, AB Funded by Canadian Institutes of Health Research No Conflicts to Declare

Acute Heart Failure in the ED: The Clinical Problem Very common presentation Potential for poor outcomes Many HF patients do not need hospital admission Little evidence to guide disposition decisions Need risk stratification tool to aid rational and safe admission decisions

Derivation of Ottawa Heart Failure Risk Scale: Acad Emerg Med 2013 Goal: Improve and standardize admission practices for HF Methods: Prospective cohort study at 6 EDs N=559 with 38% admitted Risk scale derived by logistic regression

Original Ottawa Heart Failure Risk Scale

Objectives: Prospective Validation Study (2012 2014) 1. To prospectively and clinically evaluate OHFRS in a new patient population 2014 2. To improve upon OHFRS by re evaluating predictor variables and developing a more concise model 2015

Methods 1 Design: Prospective cohort study Setting: 6 EDs of large, tertiary care Canadian hospitals Subjects: Acute HF admitted and discharged Excluded: O2 Sat < 85% on RA, HR > 120, SBP < 85 chest pain or STEMI Ethics: approved +/ informed consent Standardized Assessment: variables from history, physical routine labs, troponin, CXR, ECG quantitative NT ProBNP 3 minute walk test

Methods 2 Primary Outcome Measure serious adverse event (SAE): Death <30 days Intubation or NIV after admission MI Admission to monitored unit, or Relapse back to ED with admission within 14 days Data Analysis: Univariate association with SAE Harmonized troponin by URL Logistic regression to revise model Rounded β coefficients to create points

Patients Seen N=4,999 Patients Eligible N=1,869 Patients Enrolled N=1,100 Patient Flow Patients Excluded N=3,130 No clear increase SOB N=788 CXR shows no HF N=394 Nursing home N=376 Outside study hours N=387 Confusion, dementia N=276 Enrolled< 2 months N=200 Other N=709 Patients Not Enrolled N=769 Final Study Cohort N=1,100

Patient Characteristics Characteristic (%) N=1,100 Age in years, mean 77.7 Range 50 104 Male (%) 53.1 Ambulance arrival (%) 44.4 Duration of symptoms, hours, mean 65.5 CTAS level, median 2 Past medical history (%) Heart failure 76.7 MI/Angina 39.2 Intubation for resp distress 1.1

Patients Enrolled by Hospital (N=1,100) Foothills MC 12.8% Kingston General 12.6% Ottawa Hospital, Civic Campus 30.5% Ottawa Hospital, General Campus 14.6% U Alberta 14.0% Mount Sinai 15.6%

Patient Characteristics (N=1,100) Current Cardiac Meds (%) Diuretics 75.0 Beta blockers 68.9 Statins 62.4 Ace Inhibitors 42.5 Calcium Channel Blockers 36.3 Anti arrhythmics 6.8 Amiodarone 6.0 Sotalol 0.4 Propafenone 0.2

Patient Outcomes (%) N=1,100 Admitted to Hospital (N=629) 57.2 Critical Care Unit 9.7 Non Invasive Ventilation 3.8 Intubation 0.8 MI after admission 3.5 Death after admission 4.0 Death after discharge 1.3 Discharged from ED (N=471) 42.8 Relapse back to ED 24.2 Relapse and admitted 10.6 Death within 30 Days 1.7

Serious Adverse Events 25 20 19.4% SAEs (%) 15 10 15.6% 10.2% 5 0 Total (N=1,100) Admitted (N=629) Discharged (N=471)

Univariate Correlation with SAEs for 10 OHFRS Criteria Criterion (%) SAE No SAE (N=170) (N=930) P Value History of stroke or TIA 15.9 15.4 0.87 History of intubation 1.2 1.0 0.80 HR on ED arrival >110 20.1 11.1 <0.05 Room air SaO2 <90 32.9 22.2 <0.05 ECG acute ischemia 9.5 0.3 <0.0001 Urea >12 mmol/l 41.8 27.2 <0.001 Serum CO2 >35 mmol/l 5.4 1.4 <0.001 Troponin >0.10 ug/l 33.3 14.3 <0.0001 NT ProBNP >5,000 ng/l 63.3 49.0 <0.05 Walk test failed / too ill 70.3 53.1 <0.0001

Univariate Correlation with SAEs for Other Variables Variable (%) SAE No SAE P Value (N=170) (N=930) On Anti arrhythmic 10.6 5.6 <0.05 Ejection Fraction, mean% N=152,739 43.4 46.3 <0.05 <30% 21.7 19.5 0.53 ED Treatment IV NTG 9.4 1.8 <0.0001 BiPAP 17.1 5.0 <0.0001 Initial or repeat Troponin >URL 71.0 56.8 <0.001 >3x URL 39.1 18.7 <0.0001 >5x URL 30.2 9.9 <0.0001 NT ProBNP >10,000 ng/l 37.8 25.5 <0.05 >15,000 ng/l 27.7 13.1 <0.0001

Independent Predictors of SAE from Logistic Regression P value to enter <0.25, remove >0.10 Hosmer Lemeshow Goodness of fit p value = 0.90 Area under ROC curve = 0.72

Revised Ottawa Heart Failure Risk Scale

Classification Performance & Potential Admissions for OHFRS Cutpoints ** model developed for 1,045 patients without missing values

Observed vs Expected Probability of SAE Score Internal validation very accurate x 1,000 replications using bootstrap

Discussion Much higher admission rate Some component variables did not perform well NT probnp not useful Used troponin as multiples of URL Revised OHFRS more concise model Good internal validation

Limitations Requires further clinical validation Physicians often neglected re assessment/walk test

Conclusions: Revised OHFRS Consists of 6simple, bedside variables Estimates short term risk of SAE in acute heart failure Will assist MDs in making rational ED disposition plans Should improve and standardize admission practices, diminishing both unnecessary admissions for low risk patients, and unsafe discharge decisions for high risk patients Ultimately lead to improved safety for patients and more efficient use of hospital resources

Details of Troponin Assay by Hospital Site

Methods 3 Minute Walk Test: RN or respiratory therapist Exclude if SaO2 <90% or HR>120 Measure pulse oximetry Primary Outcome Measure serious adverse event (SAE): Death <30 days Intubation or NIV after admission MI Admission to monitored unit, or Relapse back to ED with admission within 14 days

Missed Patient Characteristics (N=769) Age in years, mean 77.7 Range 50 102 Male (%) 51.5 Admitted 60.2 Hospital (%) Ottawa H Civic, Ottawa, ON 33.3 Ottawa H General, Ottawa, ON 25.5 Foothills MC, Calgary, AB 18.7 Mount Sinai H, Toronto, ON 9.3 University Alberta H, Edmonton, AB 6.9 Kingston General H, Kingston, ON 6.4

Classification Performance of OHFRS without NT probnp (N=1,100) SAE Yes No OHFRS >2 121 410 <2 49 520 Sensitivity 71.2% Specificity 55.9% Admission 48.3%

Classification Performance of OHFRS with NT probnp (N=662) SAE Yes No OHFRS >2 95 336 <2 24 229 Sensitivity 79.8% Specificity 40.5% Admission 63.0%

Physician Comfort with Use of the OHFRS Uncomfortable 8.5% Neutral 21.8% Very Uncomfortable 3.5% Very Comfortable 17.0% Comfortable 41.5% **84 no response

Patients Seen N=4,999 Patients Eligible N=1,869 Patients Enrolled N=1,100 Patient Flow Patients Excluded N=3,130 No clear increase SOB N=788 CXR shows no HF N=394 Nursing home N=376 Outside study hours N=387 Confusion, dementia N=276 Enrolled< 2 months N=200 Other N=709 Patients Not Enrolled N=769 Final Study Cohort N=1,100 Patients Lost to Follow up N=2